Unmet Medical Needs
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix uses its specialized expertise in the development of orphan and unmet medical need indications to both in-license early stage programs and out-license late stage programs.
In-Licensing Early Stage Programs
In-licensing has historically played an important role at Soligenix. The rights to oral Beclomethasone 17,21-dipropionate (BDP), RiVax®, and ThermoVax® were in-licensed into Soligenix since 2002. In December 2012, we in-licensed dusquetide, an innate defense regular (IDR), which regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing. Our strategy is to continue to build and diversify our pipeline of products in our core competencies.
Do you have a technology in an orphan disease or with unmet medical need? Please contact us if you are interested in licensing your technology.
When Soligenix in-licenses technologies, primary considerations include:
- Comprehensive intellectual property estate
- Orphan Drug designation or Fast Track designation is feasible
- Identified lead compound with clear efficacy data in animal models
- Feasible manufacturing route identified
Out-Licensing Early Stage Programs
Soligenix is continuously looking to expand its clinical development programs, and is seeking additional partners to out-license all or portions of our programs. We are keen to advance our products through development and onto the market in as many indications as possible.
Interested in one of our technologies – please send us an email for further details.
We would consider the following types of partnering possibilities with regard to each of our programs:
HyBryte™ for Cutaneous T-Cell Lymphoma
HyBryte™ is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.
SGX942 in Oral Mucositis / SGX943 in Infectious Disease
Dusquetide is a proprietary 5-amino acid peptide for systemic delivery that regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing. Dusquetide is the active ingredient in both SGX942 and SGX943. Soligenix is seeking partners for therapeutic applications of SGX942 in all territories of the world.
Oral Beclomethasone 17,21-dipropionate (BDP) is a highly potent, topically active corticosteroid with a local effect on inflamed tissue provides a potent topical anti-inflammatory effect with less systemic toxicity than a comparably effective systemic corticosteroid. Soligenix is seeking partners for therapeutic applications of oral BDP such as Pediatric Crohn’s disease and acute radiation enteritis in all territories of the world.
Public Health Solutions – RiVax® and CiVax™
Soligenix is seeking development partners for its ricin toxin vaccine (RiVax®) and its SARS-CoV-2 coronavirus vaccine (CiVax™) in all territories of the world. These could take the form of joint venture/co-development alliances or sublicenses.
Interested in one of our technologies – please email firstname.lastname@example.org for further details.